“Patient Satisfaction With Tildrakizumab Treatment in a Phase 4 Real-World Study of Tildrakizumab in Patients With Moderate-to-Severe Plaque Psoriasis”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s134. https://doi.org/10.25251/skin.7.supp.134.